Base editing, a gene editing technology capable of installing point mutations with high efficiency and precision, was first reported a decade ago. This Review examines the evolution of base editors an...

Immune cell engagers are emerging as a strategy for deep B cell depletion in autoimmune diseases. This Review examines their mechanisms, clinical development and next-generation designs, including T c...

Immune cell engagers are emerging as a strategy for deep B cell depletion in autoimmune diseases. This Review examines their mechanisms, clinical development and next-generation designs, including T c...

Chronic obstructive pulmonary disease (COPD) is a progressive and severe respiratory disease featuring airway obstruction and recurrent exacerbations, driven by a complex network of inflammatory proce...

RNA-binding proteins (RBPs) regulate every step of cellular RNA metabolism, and their dysregulation contributes to many diseases. This Perspective describes the endogenous and disease-linked roles of ...

IL-6-targeted therapies have transformed the treatment of autoimmune diseases, but safety concerns related to the cytokine’s homeostatic functions remain. This Review examines classic and trans-signal...

There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and meta...

Discover the world’s best science and medicine | Nature.com

Agonistic antibodies initiate signalling by the receptors they target, mimicking the activities of native ligands. This Review discusses the clinical successes and failures of agonistic antibodies and...

Autophagy has a highly complex and context-dependent role in cancer, challenging the development of autophagy-modulating strategies. This Review discusses the potential of targeting autophagy to count...

Discover the world’s best science and medicine | Nature.com

Discover the world’s best science and medicine | Nature.com

Claudins are emerging as clinically actionable targets in cancer, exemplified by the approval of CLDN-18.2-directed therapy. This review examines the biological basis and therapeutic exploitation of c...

There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and meta...

Following on from its success in eradicating malignant B cells in cancer, chimeric antigen receptor (CAR) T cell therapy has been extended to treat autoimmune diseases. This Review discusses the precl...

Drug discovery for psychiatric disorders is a slow and challenging process, driven in part by reliance on symptom-based diagnostic criteria that fail to capture the underlying disease biology. In thei...

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists.

In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo manufacturing. This Review examines emerging v...

Johnson & Johnson announced a collaboration with Sail Biomedicines to develop CAR-T therapies for immune diseases and said it now has an exclusive option to acquire the closely held company.

mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzym...

Discover the world’s best science and medicine | Nature.com

Discover the world’s best science and medicine | Nature.com